New CRISPR Tool Enhances NK Cell Therapies Against Cancer

Scientists at The University of Texas MD Anderson Cancer Center have developed a novel genome-wide CRISPR screening tool that significantly improves the efficacy of natural killer (NK) cell therapies against cancer. The research, published on March 15, 2024, in the journal Cancer Cell, highlights how targeted gene editing can enhance the cancer-fighting capabilities of NK cells by identifying specific gene targets.

The study, led by Katy Rezvani, MD, PhD, professor of Stem Cell Transplantation and Cellular Therapy, reveals that NK cells become notably more effective at destroying cancer cells when certain key gene targets are removed. This breakthrough offers promising new strategies to augment the antitumor activity of chimeric antigen receptor (CAR) NK cell therapies for various cancer types.

Insights from PreCiSE

The research team utilized a comprehensive CRISPR discovery platform known as PreCiSE, specifically designed for primary human NK cells. This platform allowed scientists to uncover multiple checkpoints and pathways that regulate NK cell activity in the challenging tumor microenvironment, which often suppresses immune responses. By editing these identified targets, researchers observed enhanced innate and CAR-mediated NK cell functions, improved metabolic fitness, increased pro-inflammatory cytokine production, and expanded cytotoxic NK subsets in cancer models that previously showed resistance to treatment.

Among the three validated targets highlighted in the study—MED12, ARIH2, and CCNC—the findings underscore the broader implications of the research beyond individual genes. PreCiSE provides an unbiased framework for mapping NK cell regulators, which can be prioritized and combined to develop more effective CAR NK cell therapies.

Rezvani stated, “This has given us significant insight into the next generation of cell therapies that have the potential to be more powerful, precise, and resistant to cancer.”

Future Directions for Cell Therapy

The study’s approach involved validating the top targets in vivo across various tumor models while considering defined immune-suppressive stressors. Some of the identified regulators, such as MED12 and CCNC, intersect with pathways known from T cell biology, while others, like ARIH2, exhibit specificity to NK cells. This distinction emphasizes the utility of a platform tailored specifically for NK cell research.

The advancements made by the Rezvani Laboratory in engineered NK cell therapies have already led to clinical trials for patients suffering from advanced hematologic and solid malignancies. Through the Institute for Cell Therapy Discovery & Innovation, Rezvani and her team aim to continue developing impactful cell therapies that meet patient needs.

The latest findings are expected to play a crucial role in further enhancing the efficacy of CAR NK cells across more cancer types. This ongoing research is supported by contributions from various philanthropic sources, including lead commitments from the Marcus Foundation, Inc., and the National Institutes of Health, which provides essential funding for innovative cancer research.

As researchers continue to explore these promising avenues, the potential for more effective cancer therapies remains a focal point of ongoing efforts in the field of immunotherapy.